This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Marina Biotech, Inc.
Drug Names(s): PYY
Description: Nastech's formulation of PYY3-36 is given intranasally. PYY3-36 is a segment of the gut hormone PYY, which is secreted in response to a meal and both inhibits stomach motility and reduces appetite. PYY also reduces concentrations of ghrelin, a hormone that stimulates appetite.
Deal Structure: On September 27, 2004, Nastech Pharmaceutical announced that it had acquired exclusive worldwide rights to the Imperial College Innovations and Oregon Health & Science University PYY patent applications in the field of intranasal delivery of PYY and the use of glucagon-like peptide-1 (GLP-1) used in conjunction with PYY for the treatment of obesity, diabetes and other metabolic conditions. The license agreement is with Thiakis Limited, the exclusive licensee of the applications, and relates to work in the field of obesity conducted by scientists at the Imperial College London, UK and Oregon Health & Science University, Portland, Oregon. Specific terms of the agreement are undisclosed, however in addition to an equity investment by Nastech in Thiakis, Thiakis is entitled to receive license fees, milestone payments and patent-based royalties.
Discontinued Merck Agreement
Under the terms of their agreement, Nastech and Merck will jointly develop PYY. Merck will assume...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: